PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
about
The PTEN tumor suppressor gene and its role in lymphoma pathogenesisPI3K isoform-selective inhibitors: next-generation targeted cancer therapiesDual kinase-bromodomain inhibitors for rationally designed polypharmacologyTherapeutic targeting of cancers with loss of PTEN function.Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Isolation of side population cells from endometrial cancer cells using a violet laser diode.Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells.In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.Epistatic interactions and drug response.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc.Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.Endometrial Carcinoma: Specific Targeted Pathways.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text MiningInhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samplesEndometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.The PI3K Pathway in Human Disease.Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle.Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
P2860
Q26776527-A4E91570-3612-4125-B78C-ACD6DBCCB68AQ26781294-2EF8A2E2-15A3-4427-9E7E-6CDA948E4C51Q27681935-53348590-866D-4344-9C90-6F9838BECDE4Q27852764-87D1A94C-6D92-4AB7-BA23-87DA0F7F9491Q28550300-B4B87CBE-67EF-4205-AAAE-3437DE2428E2Q34103963-35BB6623-B573-464B-A7FC-8A3105B04F33Q35007698-D1E65F50-FA93-41F0-B11D-D328796D0F77Q35236484-11A36C4D-AD16-4BBA-8735-DDAE7ECE6613Q35260766-1C2BAFF4-EF59-45C0-839F-594DE607BD7CQ36087843-BCCDAA0D-D4C5-4103-9DF4-FF39AFA30EB0Q36422289-4CFB2F48-6C84-4EA9-B9E8-0A146A17F64FQ37082531-745ED82B-C863-4EF4-ADC2-1EA59B76B291Q37381834-1B540060-3B01-486E-9059-E3FC080D2E99Q37587308-EF0F3169-DFB5-45A2-8C85-1370F2237A53Q37702500-1AA842C2-4A41-41BF-AA79-7C854F76F5D3Q38150749-8A4E2279-D780-483D-BC74-0C52F5D21206Q38265574-332CB57D-30EE-4FA7-8B72-DF099CC7AF83Q38699761-B47A50E7-E62E-4020-A82A-BD1876A1A055Q38710557-D98FF60E-D240-4309-A6F5-A0A3961DDC10Q38734266-07BEA122-2301-4DB2-B499-59B9405FE199Q38745816-15F21C5B-56B2-483E-B29D-B1E637282760Q38852858-4EBF0D3B-2F3F-47BE-9C9A-1155C53231A8Q39026766-6BBE1DDF-8CD2-4781-A6D0-3CB7891B6EEFQ39226787-D895AC09-E033-4659-B48B-2DD0278FACA3Q39752527-9A8185BC-CDD5-41C4-B35B-C3ABCE9C412CQ40543038-38C15A35-A211-4494-B1D9-019FF3F0DB1FQ41468431-D0B98982-FFC5-4600-9C9F-B22BFDF07FF3Q41708245-5A8E6A8F-F509-4716-875C-5346BB669E45Q42030378-47C91204-F1E4-4251-98D7-75EA26E30097Q42118139-F6A4D406-2300-4147-A88C-D29ED50FA1BAQ46546002-E5353B5B-84DB-44D6-A897-D88D7AD8D7AAQ47736935-78348E58-B9EE-4011-BB98-67EAAA3F50FAQ47748552-06486389-8022-42E1-A67D-3CE0FDF1BA6AQ48640596-3E388CEA-1A02-409C-B7A1-C1445AB46842Q49180082-CC85D635-9D5C-43CA-B1E7-9A651EE56B91Q49864928-E09C76C7-87B8-4C71-A0CB-473062FB995CQ52733765-6CB26F32-64CB-41C8-A40A-F34F0ED48B1DQ52951832-794961D1-5366-4B97-B6BE-153862910A7EQ53730678-53A990AC-5ED7-49D2-81CC-BBE5EB98DF56Q55553003-347EC159-7B6D-4E62-88D3-A8DBEF12A271
P2860
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
@en
type
label
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
@en
prefLabel
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
@en
P2860
P50
P1476
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
@en
P2093
Maryou B Lambros
Patricia H Warne
P2860
P304
P356
10.1158/1078-0432.CCR-12-3815
P407
P577
2013-05-14T00:00:00Z